Endometriosis - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Endometriosis - Pipeline Review, H1 2016', provides an overview of the Endometriosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Endometriosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Endometriosis - The report reviews pipeline therapeutics for Endometriosis by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Endometriosis therapeutics and enlists all their major and minor projects - The report assesses Endometriosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Endometriosis Reasons to Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Endometriosis - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 8 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Endometriosis Overview 11 Therapeutics Development 12 Pipeline Products for Endometriosis - Overview 12 Pipeline Products for Endometriosis - Comparative Analysis 13 Endometriosis - Therapeutics under Development by Companies 14 Endometriosis - Therapeutics under Investigation by Universities/Institutes 16 Endometriosis - Pipeline Products Glance 17 Late Stage Products 17 Clinical Stage Products 18 Early Stage Products 19 Unknown Stage Products 20 Endometriosis - Products under Development by Companies 21 Endometriosis - Products under Investigation by Universities/Institutes 23 Endometriosis - Companies Involved in Therapeutics Development 24 AbbVie Inc. 24 Addex Therapeutics Ltd 25 APAvadis Biotechnologies Srl 26 Astellas Pharma Inc. 27 Bayer AG 28 Dongkook Pharmaceutical Co., Ltd. 29 ElexoPharm GmbH 30 EndoCeutics, Inc. 31 Euroscreen S.A. 32 Evotec AG 33 Forendo Pharma Limited 34 GlaxoSmithKline Plc 35 Kissei Pharmaceutical Co., Ltd. 36 Lipicard Technologies Limited 37 Nippon Shinyaku Co., Ltd. 38 Orphagen Pharmaceuticals, Inc. 39 Philogen S.p.A. 40 Repros Therapeutics Inc. 41 SK Chemicals Co., Ltd. 42 Takeda Pharmaceutical Company Limited 43 ValiRx Plc 44 Endometriosis - Therapeutics Assessment 45 Assessment by Monotherapy Products 45 Assessment by Combination Products 46 Assessment by Target 47 Assessment by Mechanism of Action 50 Assessment by Route of Administration 52 Assessment by Molecule Type 54 Drug Profiles 56 (anastrozole + levonorgestrel) - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 ASP-1707 - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 BAY-1128688 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 bentamapimod - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Drug to Inhibit C-Jun for Endometriosis - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Drugs for Endometriosis - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 Drugs for Endometriosis and Uterine Fibroids - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 elagolix sodium - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 epelsiban besylate - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 ESN-364 - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 EVE-104 - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 FP-5677 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 goserelin biosimilar - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 KLH-2109 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 LT-6121 - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 MIA-602 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Monoclonal Antibody to Antagonize Prolactin Receptor for Endometriosis - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 NS-580 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 Peptides for Hepatic Tumor and Endometriosis - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Peptides to Inhibit Aminopeptidase A for Hepatic (Liver) Tumor and Endometriosis - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 PGL-2001 - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Recombinant Protein for Endometriosis and Ovarian Hyperstimulation Syndrome - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 relugolix - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 SKI-2670 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Small Molecule to Antagonize FSH Receptor for Women's Health - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 SR-16234 - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 telapristone acetate - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 Tetravil - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 triptorelin biosimilar - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 VAL-201 - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 vilaprisan - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 VPE-001 - Drug Profile 103 Product Description 103 Mechanism of Action 103 R&D Progress 103 VPEA-004 - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 Endometriosis - Recent Pipeline Updates 105 Endometriosis - Dormant Projects 120 Endometriosis - Discontinued Products 122 Endometriosis - Product Development Milestones 123 Featured News & Press Releases 123 Feb 10, 2016: AbbVie Announces Positive Top-Line Results From Second Phase 3 Study Investigating Elagolix in Patients with Endometriosis 123 Dec 21, 2015: Repros Updates Proellex Program 124 Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on BAY 98-7196 at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA 124 Mar 24, 2015: Bayer to present new preclinical, early clinical and epidemiological data on Vilaprisan at 62nd Annual Scientific Meeting, March 25-28, 2015, in San Francisco, CA 125 Feb 26, 2015: New Endometriosis Patent Grant for ValiRx 126 Jan 15, 2015: Clinical Trial and Development Update on VAL201 for oncology indications 127 Jan 08, 2015: Abbvie Announces Positive Top-Line Results From Phase 3 Study Of Investigational Medicine Elagolix In Patients With Endometriosis 127 Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting 128 Apr 01, 2014: ValiRx Provides Updated On Anti-cancer Therapeutic VAL201 128 Mar 13, 2014: New drug candidate showed efficacy in human endometriosis samples 129 Appendix 130 Methodology 130 Coverage 130 Secondary Research 130 Primary Research 130 Expert Panel Validation 130 Contact Us 130 Disclaimer 131
List of Tables
Number of Products under Development for Endometriosis, H1 2016 12 Number of Products under Development for Endometriosis - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 15 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Comparative Analysis by Late Stage Development, H1 2016 17 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Development, H1 2016 19 Comparative Analysis by Unknown Stage Development, H1 2016 20 Products under Development by Companies, H1 2016 21 Products under Development by Companies, H1 2016 (Contd..1) 22 Products under Investigation by Universities/Institutes, H1 2016 23 Endometriosis - Pipeline by AbbVie Inc., H1 2016 24 Endometriosis - Pipeline by Addex Therapeutics Ltd, H1 2016 25 Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H1 2016 26 Endometriosis - Pipeline by Astellas Pharma Inc., H1 2016 27 Endometriosis - Pipeline by Bayer AG, H1 2016 28 Endometriosis - Pipeline by Dongkook Pharmaceutical Co., Ltd., H1 2016 29 Endometriosis - Pipeline by ElexoPharm GmbH, H1 2016 30 Endometriosis - Pipeline by EndoCeutics, Inc., H1 2016 31 Endometriosis - Pipeline by Euroscreen S.A., H1 2016 32 Endometriosis - Pipeline by Evotec AG, H1 2016 33 Endometriosis - Pipeline by Forendo Pharma Limited, H1 2016 34 Endometriosis - Pipeline by GlaxoSmithKline Plc, H1 2016 35 Endometriosis - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 36 Endometriosis - Pipeline by Lipicard Technologies Limited, H1 2016 37 Endometriosis - Pipeline by Nippon Shinyaku Co., Ltd., H1 2016 38 Endometriosis - Pipeline by Orphagen Pharmaceuticals, Inc., H1 2016 39 Endometriosis - Pipeline by Philogen S.p.A., H1 2016 40 Endometriosis - Pipeline by Repros Therapeutics Inc., H1 2016 41 Endometriosis - Pipeline by SK Chemicals Co., Ltd., H1 2016 42 Endometriosis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 43 Endometriosis - Pipeline by ValiRx Plc, H1 2016 44 Assessment by Monotherapy Products, H1 2016 45 Assessment by Combination Products, H1 2016 46 Number of Products by Stage and Target, H1 2016 48 Number of Products by Stage and Mechanism of Action, H1 2016 51 Number of Products by Stage and Route of Administration, H1 2016 53 Number of Products by Stage and Molecule Type, H1 2016 55 Endometriosis Therapeutics - Recent Pipeline Updates, H1 2016 105 Endometriosis - Dormant Projects, H1 2016 120 Endometriosis - Dormant Projects (Contd..1), H1 2016 121 Endometriosis - Discontinued Products, H1 2016 122
List of Figures
Number of Products under Development for Endometriosis, H1 2016 12 Number of Products under Development for Endometriosis - Comparative Analysis, H1 2016 13 Number of Products under Development by Companies, H1 2016 14 Number of Products under Investigation by Universities/Institutes, H1 2016 16 Comparative Analysis by Clinical Stage Development, H1 2016 18 Comparative Analysis by Early Stage Products, H1 2016 19 Assessment by Monotherapy Products, H1 2016 45 Assessment by Combination Products, H1 2016 46 Number of Products by Top 10 Targets, H1 2016 47 Number of Products by Stage and Top 10 Targets, H1 2016 47 Number of Products by Top 10 Mechanism of Actions, H1 2016 50 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 50 Number of Products by Routes of Administration, H1 2016 52 Number of Products by Stage and Routes of Administration, H1 2016 52 Number of Products by Molecule Types, H1 2016 54 Number of Products by Stage and Molecule Types, H1 2016 54
Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries sRead More...
Global automotive ECU market is projected to be valued at USD 45.98 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising use in infotainment systems coupled with high deployment in electric vehicles applications is expectedRead More...
Global PP (Polypropylene) nonwoven fabric market size is anticipated to be valued at USD 30.6 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing usage of hygiene products such as incontinence products and baby diapers isRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.